Not exactly a post beaming with enthusiasm but as it is the 6 month mark since issuing the convertible note & conversion 7 months away the whole thing is looking a bit ummmmmm ?
If it did reach maturity where the share price is today & measuring against the specified discount based on objectives achieved ie. 40% at present with no deal comparable to Jannsen yet reached then issue would be at 1.2c per share certainly along way from the 5.2c highlighted with the initial announcement at the time being a 104% premium to the then price but I guess it always looked a long shot pressing that figure against all the clauses that would bring it lower than the "pretty" figure. Again to reach that 5.2c means the overall share price has to be significantly above 5.2c for it to materialize that way in which case everybody would be happy.
Anyway time will tell - 7 months & 1 week to go, time to pull rabbits out of hats & maybe a shareholder update somewhere along the way :-)
- Forums
- ASX - By Stock
- Ann: Converting Note Placement
PYC
pyc therapeutics limited
Add to My Watchlist
3.03%
!
$1.28

Not exactly a post beaming with enthusiasm but as it is the 6...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.28 |
Change
-0.040(3.03%) |
Mkt cap ! $746.5M |
Open | High | Low | Value | Volume |
$1.32 | $1.35 | $1.28 | $764.7K | 579.2K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | $1.28 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.30 | 40248 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 4000 | 1.275 |
1 | 13987 | 1.265 |
2 | 16060 | 1.260 |
1 | 12000 | 1.255 |
2 | 2800 | 1.250 |
Price($) | Vol. | No. |
---|---|---|
1.300 | 40248 | 3 |
1.330 | 5000 | 1 |
1.345 | 53113 | 2 |
1.350 | 22000 | 2 |
1.360 | 5958 | 1 |
Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
Previous Video
Next Video
SPONSORED BY The Market Online